GER-009-06-AVX Early Therapy in Multiple Sclerosis

Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis

NCT00599274 ·Status: COMPLETED

Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis

NCT00037102 ·Status: COMPLETED ·Phase: PHASE4

Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients

NCT00784836 ·Status: TERMINATED ·Phase: PHASE3

Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis

NCT00324506 ·Status: COMPLETED ·Phase: PHASE2

Immunogenicity and Safety Study of Serum-Free Avonex

NCT00912860 ·Status: COMPLETED ·Phase: PHASE2

A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00676715 ·Status: COMPLETED ·Phase: PHASE2

Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)

NCT00986960 ·Status: WITHDRAWN ·Phase: PHASE2

Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS

NCT00168766 ·Status: COMPLETED ·Phase: PHASE4

A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)

NCT00292266 ·Status: COMPLETED ·Phase: PHASE3

Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects

NCT00828204 ·Status: COMPLETED ·Phase: PHASE3

Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)

NCT04032158 ·Status: TERMINATED ·Phase: PHASE3

COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS

NCT00675883 ·Status: COMPLETED

Cognitive Effects of Immunomodulatory Drugs in MS

NCT00229502 ·Status: COMPLETED

Study of Evobrutinib in Participants With RMS

NCT04032171 ·Status: TERMINATED ·Phase: PHASE3

Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis

NCT00223301 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers

NCT00913666 ·Status: COMPLETED ·Phase: PHASE4

Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study

NCT01272128 ·Status: COMPLETED

Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS)

NCT01181115 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis

NCT00030966 ·Status: COMPLETED ·Phase: PHASE3

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

NCT01864148 ·Status: COMPLETED ·Phase: PHASE2

Safety of Avonex Treatment in Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta Therapy

NCT00493077 ·Status: COMPLETED ·Phase: PHASE4

Open-Label Safety Extension Study of Avonex

NCT00915460 ·Status: COMPLETED ·Phase: PHASE4

Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS

NCT00463710 ·Status: COMPLETED

Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.

NCT00037115 ·Status: WITHDRAWN ·Phase: PHASE4

An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis

NCT00398528 ·Status: TERMINATED